In the fast-evolving field of interventional cardiology, Simplicardiac is set to make an impact with its groundbreaking presentation, “Automated Arterial Access Site Management,” which will be featured during the TCT Innovation 1: The Cath Lab of the Future: Remaining Needs and Futuristic Trends session on October 28, 2024. This session, part of the prestigious Transcatheter Cardiovascular Therapeutics (TCT) conference, highlights cutting-edge technologies and trends poised to shape the future of cardiovascular care. The platform of innovation: TCT and Cardiovascular Research Foundation.
TCT, hosted by the Cardiovascular Research Foundation in New York, stands as a global beacon for interventional cardiovascular medicine. Over the past decade, its scientific program has spotlighted the latest technological advancements against a backdrop of ongoing global innovation discourse, focusing on the challenges and opportunities in the field. Since 2004, TCT has been at the forefront of identifying and nurturing groundbreaking technologies through its public competition, aiming to transform patient diagnostics and care in cardiovascular diseases.
Simplicardiac’s breakthrough: revolutionizing patient monitoring
Simplicardiac’s innovative approach to integrating treatment and monitoring into a novel device family aims to enhance patient outcomes while reducing the workload on medical personnel. By addressing unmet clinical needs and presenting compelling pre-clinical data, our technology has earned a coveted spot in the finals.
This October in Washington D.C., Simplicardiac will demonstrate how their technology targets these unmet needs, offering a potential revolution in patient care post-endovascular procedures. The competition, not only highlights the dynamic shifts within the field but also underscores the significant strides made in minimally invasive treatments for coronary and structural heart diseases in recent years.
Stay tuned as Simplicardiac presents its research findings and innovative solutions at one of the most awaited events in the cardiovascular medical community. Their participation not only marks a significant achievement but also sets the stage for potential transformative changes in how cardiovascular care is delivered globally.
Join us at TCT for Simplicardiac’s presentation
We invite all interested parties to attend TCT for a firsthand look at Simplicardiac’s presentation. The presentation titled: Controlled Arterial Access Site Monitoring and Management System (Simplicardiac) will be made on October 28, 2024, at 08:18 AM Eastern Time, as part of the TCT Innovation 1: The Cath Lab of the Future: Remaining Needs and Futuristics Trends Session – Innovation & FDA track – Walter E. Washington Convention Center | Lower Level | Innovation & Exhibit Hall (Halls A-C) | Innovation Theater.
About Simplicardiac S.A.
Simplicardiac S.A. is a privately held medical technology company specializing in the development of innovative devices for interventional cardiology. With a focus on arterial access site management, Simplicardiac is committed to advancing patient care and outcomes by addressing critical challenges in vascular health. The company leverages cutting-edge research and engineering to create solutions that enhance safety, efficiency, and ease of use worldwide for cardiologists and healthcare providers. Simplicardiac’s mission is to deliver impactful technologies that improve procedural success and patient well-being, setting new standards in cardiovascular medicine.
